厄达替尼的适应症

Erdafitinib is a targeted therapy drug targeting specific gene mutations and plays an important role in the treatment of urinary system tumors. This article will introduce in detail the indications, pharmacological mechanism of action and contraindications of this drug. Erdafitinib is mainly used for patients with urothelial cancer with specific gene mutations. It exerts anti-tumor effects by inhibiting the FGFR signaling pathway. Knowing the contraindications can avoid the risk of inappropriate medication.

Indications of Erdafitinib

Erdafitinib has a clear clinical application scope and is mainly targeted at tumor patients with specific gene mutation types. Understanding its indications will help accurately select the treatment population.

Main treatment population

Erdafitinib is suitable for adult patients with locally advanced or metastatic urothelial carcinoma who carry FGFR2 or FGFR3 gene mutations or fusions and whose disease has progressed during or after platinum-based chemotherapy.

Genetic testing requirements

Prior to use, the presence of FGFR3 genetic alterations in the tumor must be confirmed through an FDA-approved companion diagnostic test. This precision medicine model ensures that the drug is only used in patient groups that may benefit.

Limitations on the number of treatment lines

This drug is approved for patients whose disease has progressed after receiving at least one systemic therapy. It is usually used as a second-line or later-line treatment option and is not recommended for treatment-naïve patients.

Patients should undergo professional genetic testing to confirm suitability and should not use drugs at will.

Efficacy and role of Erdafitinib

Erdafitinib exerts anti-tumor effects through a unique pharmacological mechanism, and its therapeutic effect has been verified in clinical studies.

Mechanism of action

As a potent and selective inhibitor of FGFR1-4, erdafitinib can block the FGFR signaling pathway and inhibit tumor cell proliferation and survival. This targeting makes it particularly effective against tumors with FGFR mutations.

Clinical Effects

Pivotal clinical trials show that erdafitinib can produce durable tumor responses in patients with FGFR-mutated urothelial cancer. The objective response rate reaches a clinically meaningful level, and some patients can achieve long-term disease control.

Therapeutic Advantages

Compared with traditional chemotherapy, erdafitinib has better targeting and more controllable adverse reactions. Its oral delivery method also improves treatment convenience.

Erdafitinib provides a new treatment option for patients with specific gene mutations and represents the application of precision medicine in the field of urological tumors.

Contraindications of Erdafitinib

Erdafitinib is not suitable for all patients and needs to be contraindicated or used with caution in some cases.

Absolute contraindications

It is contraindicated in patients who are allergic to erdafitinib or any excipients. It is not recommended for patients with severe liver function impairment, because the drug is mainly metabolized by the liver.

Restrictions for special groups

Contraindicated in pregnant women. Animal studies have shown that the drug has embryo-fetal toxicity. Breast-feeding women should stop breastfeeding. The safety and effectiveness in pediatric patients have not yet been established.

Drug Interaction Contraindications

Avoid co-administration with strong CYP3A4 inducers or inhibitors, which may significantly affect drug concentration. Be careful with combined use with drugs that may alter serum phosphate levels.

Patients should truthfully inform the doctor of their health status and medication history, and strictly follow the doctor's instructions when taking medication.